JP2010525073A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010525073A5 JP2010525073A5 JP2010506460A JP2010506460A JP2010525073A5 JP 2010525073 A5 JP2010525073 A5 JP 2010525073A5 JP 2010506460 A JP2010506460 A JP 2010506460A JP 2010506460 A JP2010506460 A JP 2010506460A JP 2010525073 A5 JP2010525073 A5 JP 2010525073A5
- Authority
- JP
- Japan
- Prior art keywords
- mglur7
- modulator
- use according
- medicament
- aging
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100038294 Metabotropic glutamate receptor 7 Human genes 0.000 claims 4
- 108010038449 metabotropic glutamate receptor 7 Proteins 0.000 claims 4
- 206010011878 Deafness Diseases 0.000 claims 2
- 230000032683 aging Effects 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 231100000888 hearing loss Toxicity 0.000 claims 2
- 230000010370 hearing loss Effects 0.000 claims 2
- 208000016354 hearing loss disease Diseases 0.000 claims 2
- YRQCDCNQANSUPB-UHFFFAOYSA-N AMN082 dihydrochloride Chemical group Cl.Cl.C=1C=CC=CC=1C(C=1C=CC=CC=1)NCCNC(C=1C=CC=CC=1)C1=CC=CC=C1 YRQCDCNQANSUPB-UHFFFAOYSA-N 0.000 claims 1
- 206010036626 Presbyacusis Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000003204 osmotic effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91352007P | 2007-04-23 | 2007-04-23 | |
| US488007P | 2007-11-30 | 2007-11-30 | |
| US2100708P | 2008-01-14 | 2008-01-14 | |
| PCT/US2008/061330 WO2008131439A1 (en) | 2007-04-23 | 2008-04-23 | Treatment and/or prevention of presbycusis by modulation of metabotropic glutamate receptor 7 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010525073A JP2010525073A (ja) | 2010-07-22 |
| JP2010525073A5 true JP2010525073A5 (OSRAM) | 2011-06-02 |
Family
ID=39580582
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010506460A Pending JP2010525073A (ja) | 2007-04-23 | 2008-04-23 | 代謝型グルタミン酸受容体７の調節による老人性難聴の治療及び／又は予防 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20100197800A1 (OSRAM) |
| EP (1) | EP2150244A1 (OSRAM) |
| JP (1) | JP2010525073A (OSRAM) |
| WO (1) | WO2008131439A1 (OSRAM) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11969501B2 (en) | 2008-04-21 | 2024-04-30 | Dompé Farmaceutici S.P.A. | Auris formulations for treating otic diseases and conditions |
| EP2278999B1 (en) | 2008-04-21 | 2025-01-29 | Dompé farmaceutici S.p.A. | Auris formulations for treating otic diseases and conditions |
| BRPI0912482A2 (pt) | 2008-05-14 | 2020-08-18 | Otonomy, Inc | composições de corticosteróide de liberação controlada e métodos para o tratamento de distúrbios auriculares |
| US8846770B2 (en) | 2008-06-18 | 2014-09-30 | Otonomy, Inc. | Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders |
| WO2010011466A2 (en) | 2008-06-27 | 2010-01-28 | Otonomy, Inc. | Controlled-release cns modulating compositions and methods for the treatment of otic disorders |
| US8318817B2 (en) | 2008-07-21 | 2012-11-27 | Otonomy, Inc. | Controlled release antimicrobial compositions and methods for the treatment of otic disorders |
| US8784870B2 (en) | 2008-07-21 | 2014-07-22 | Otonomy, Inc. | Controlled release compositions for modulating free-radical induced damage and methods of use thereof |
| US8496957B2 (en) | 2008-07-21 | 2013-07-30 | Otonomy, Inc | Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders |
| AU2009307825A1 (en) | 2008-10-22 | 2010-04-29 | Rick FRIEDMAN | Treatment and/or prevention of inner ear conditions by modulation of a metabotropic glutamate receptor |
| US9486405B2 (en) | 2013-08-27 | 2016-11-08 | Otonomy, Inc. | Methods for the treatment of pediatric otic disorders |
| WO2015120453A1 (en) | 2014-02-10 | 2015-08-13 | University Of South Florida | Hormone treatment for age-related hearing loss-presbycusis |
| EP3459939A1 (en) | 2017-09-26 | 2019-03-27 | Pragma Therapeutics | Novel heterocyclic compounds as modulators of mglur7 |
| GB202106871D0 (en) | 2021-05-13 | 2021-06-30 | Addex Pharmaceuticals Sa | Novel compounds |
| GB202106872D0 (en) | 2021-05-13 | 2021-06-30 | Addex Pharmaceuticals Sa | Novel compounds |
| GB202216962D0 (en) | 2022-11-14 | 2022-12-28 | Addex Pharmaceuticals Sa | Novel compounds |
| GB202216960D0 (en) | 2022-11-14 | 2022-12-28 | Addex Pharmaceuticals Sa | Novel compounds |
| GB202216963D0 (en) | 2022-11-14 | 2022-12-28 | Addex Pharmaceuticals Sa | Novel compounds |
| KR102847157B1 (ko) | 2023-01-17 | 2025-08-20 | 고려대학교 산학협력단 | 글루타민을 유효성분으로 포함하는 난청 예방 또는 치료용 약학 조성물 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001234420A1 (en) * | 2000-02-03 | 2001-08-14 | Eli Lilly And Company | Potentiators of glutamate receptors |
| AU2004226450A1 (en) * | 2003-03-26 | 2004-10-14 | Merck & Co. Inc. | Benzamide modulators of metabotropic glutamate receptors |
| AU2005291075A1 (en) * | 2004-10-05 | 2006-04-13 | Merz Pharma Gmbh & Co. Kgaa | Novel cyclic and acyclic propenones for treating CNS disorders |
| WO2006071730A1 (en) * | 2004-12-27 | 2006-07-06 | Astrazeneca Ab | Pyrazolone compounds as metabotropic glutamate receptor agonists for the treatment of neurological and psychiatric disorders |
| JP2009503069A (ja) * | 2005-08-05 | 2009-01-29 | アストラゼネカ アクチボラグ | 三環式ベンゾイミダゾール類、および代謝性グルタミン酸塩受容体のモジュレータとしてのそれらの使用 |
| JP2009509921A (ja) * | 2005-08-12 | 2009-03-12 | アストラゼネカ アクチボラグ | 置換イソインドロン類及び代謝調節型グルタミン酸受容体増強剤としてのその使用 |
| GB0517740D0 (en) * | 2005-08-31 | 2005-10-12 | Novartis Ag | Organic compounds |
| TW200819458A (en) * | 2006-06-23 | 2008-05-01 | Merz Pharma Gmbh & Co Kgaa | Metabotropic glutamate receptor modulators |
-
2008
- 2008-04-23 US US12/597,054 patent/US20100197800A1/en not_active Abandoned
- 2008-04-23 EP EP08746706A patent/EP2150244A1/en not_active Ceased
- 2008-04-23 WO PCT/US2008/061330 patent/WO2008131439A1/en not_active Ceased
- 2008-04-23 JP JP2010506460A patent/JP2010525073A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010525073A5 (OSRAM) | ||
| JP2010285439A5 (OSRAM) | ||
| CA2683786C (en) | Use of tapentadol in the treatment of pain and with a reduced incidence of tapentadol-induced side-effects | |
| BRPI0806531A2 (pt) | Composto, composição farmacêutica, agente terapêutico, e, uso do composto. | |
| IL199187A (en) | Indole history, pharmaceuticals including them and their use in the manufacture of medicines | |
| IL234166B (en) | Isoindoline compounds, a pharmaceutical composition containing it and its use in the preparation of a medicine | |
| IL233677A (en) | Benzysacazole Compounds Aminopyrazolo-Primidine Converted, Pharmaceuticals Containing Them, and Use of Drug Manufacturing Composition | |
| JP2007527914A5 (OSRAM) | ||
| BRPI0822885A2 (pt) | Implemento para cuidado oral, método para administrar um agente ativo, e, kit para cuidado oral | |
| CL2007001993A1 (es) | Compuestos derivados de pirimidilciclopentanos hidroxilados y metoxilados; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodegenerat | |
| JP2011511805A5 (OSRAM) | ||
| WO2007135193A3 (fr) | Forme pharmaceutique orale multimicroparticulaire a liberation prolongee comprenant des moyens anti-mesusage et resistant a l'alcool | |
| BRPI0810390A2 (pt) | Película, composição, e, métodos para administrar um material ativo, para melhorar a estabilidade de uma película e para manter a saúde sistêmica de um mamífero | |
| CL2007001992A1 (es) | Compuestos derivados de pirimidilciclopentanos; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodege | |
| JP2007302683A5 (OSRAM) | ||
| IL206952A (en) | History of Aminodia Hydrothiazine, medicinal preparations containing them, and their use in the preparation of medicines | |
| IL211120A (en) | Compound, tetracycline converted at position 7c with fluorine, a pharmaceutical preparation containing it and its use in the preparation of drugs for the treatment of bacteria-caused infection | |
| FR2934156B1 (fr) | Medicament appetissant a administration orale sous forme solide | |
| BRPI0814666A2 (pt) | composição farmacêutica para a administração oral, uso de uma formulação. processo para a preparação de uma forma de dosagem sólida, e, forma de dosagem sólida | |
| IL191310A (en) | A variant of the factor xa enhancer hemostasis, a pharmaceutical product containing it, and its use in the preparation of drugs for the treatment of hemostasis-related diseases | |
| BRPI0807285A2 (pt) | "composição, método para preparar composição farmacêutica, forma unitária de dosagem, método para admnistrar um agente biologicamente ativo a um animal necessitando o agente, método para aumentar a biodisponibilidade de um agente biologicamente ativo, método para preparar uma composição e composto" | |
| IL201730A (en) | History 1h - Benzaimidazole – 2 – Il – Profile – Methyl – Amino – Ethyl – 5 – Aryl – Bicyclo [2.2.2] Oct – 5 – Ann – 2 – All, Pharmaceutical preparations containing them and their use in the preparation of drugs | |
| DK2083638T3 (da) | Smagsfrigivende kerner og deres anvendelse i tyggegummi | |
| CL2007003519A1 (es) | Compuestos derivados de quinolina sustituida; proceso de preparacion; compuesto intermediario; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de una infeccion bacteriana. | |
| WO2009064681A3 (en) | Liquid compositions comprising valsartan |